Board Meeting Details

The Board of Directors meeting was held on Thursday, 12th November 2026 from 04:00 PM to 06:30 PM.

Key Decisions

  • Considered and approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and Half year ended 30th September 2026
  • Took note of the Limited Review Report issued by the Statutory Auditors on the financial results

Financial Results Availability

The financial results are available on the company website at https://concorddrugs.in/investor-relations and on BSE website. Will be published in newspapers as per SEBI requirements.

Standalone Financial Performance (Amounts in ₹ Lakhs)

Balance Sheet as at 30-Sep-2026

  • Total Assets: 9,430.82 (vs 7,185.48 as at 31-Mar-2026)
  • Equity Share Capital: 1,317.50 (unchanged)
  • Other Equity: 3,754.68 (vs 3,533.89 as at 31-Mar-2026)
  • Total Equity: 5,072.18 (vs 4,851.39 as at 31-Mar-2026)
  • Non-current liabilities: 850.59 (vs 531.69 as at 31-Mar-2026)
  • Current liabilities: 3,508.05 (vs 1,802.40 as at 31-Mar-2026)

Profit & Loss for Half Year Ended 30-Sep-2026

  • Revenue from Operations: 4,157.79
  • Other Income: 6.43
  • Total Revenue: 4,164.23
  • Total Expenses: 3,859.57
  • Profit before tax: 304.65
  • Tax Expense: 83.86 (Current tax), 85.60 (Deferred tax), -1.74 (Net)
  • Profit for the period: 220.79
  • Earnings Per Share (Basic & Diluted): ₹1.68

Consolidated Financial Performance (Amounts in ₹ Lakhs)

Profit & Loss for Half Year Ended 30-Sep-2026

  • Revenue from Operations: 4,169.21
  • Other Income: 6.43
  • Total Revenue: 4,175.65
  • Total Expenses: 3,870.53
  • Profit before tax: 305.12
  • Tax Expense: 83.98 (Current tax), 85.67 (Deferred tax), -1.69 (Net)
  • Profit for the period: 221.14
  • Earnings Per Share (Basic & Diluted): ₹1.68

Quarterly Performance Trends

Standalone Quarterly (₹ Lakhs)

  • Sep-26 Quarter: Revenue 2,080.95, Profit 109.74, EPS ₹0.83
  • Jun-26 Quarter: Revenue 2,094.70, Profit 111.40, EPS ₹0.85
  • Sep-25 Quarter: Revenue 1,027.85, Profit 19.22, EPS ₹0.19

Consolidated Quarterly (₹ Lakhs)

  • Sep-26 Quarter: Revenue 2,080.95, Profit 109.74, EPS ₹0.83
  • Jun-26 Quarter: Revenue 2,094.70, Profit 111.40, EPS ₹0.85
  • Sep-25 Quarter: Revenue 1,027.85, Profit 19.22, EPS ₹0.19

Key Financial Metrics

  • Paid-up Equity Share Capital: ₹1,317.50 lakhs (Face value ₹10 per share)
  • EPS not strictly comparable due to increase in weighted average number of equity shares outstanding during quarter ended 31.03.2026
  • Preferential Allotment: 31,75,000 equity shares at ₹36.50 per share
  • Equity share capital increased by over 33% but EPS improved, demonstrating stronger earnings generation

Cash Flow Statements (Standalone)

Six Months Ended 30-Sep-2026 (₹ Lakhs)

  • Net cash flow from operating activities: -748.54
  • Net cash flow from investing activities: -38.40
  • Net cash flow from financing activities: 787.02
  • Net decrease in cash: 0.09
  • Cash equivalents at end: 27.18

Auditor Review

Pundarikashyam and Associates, Chartered Accountants (FRN: 011330S) issued:

1. Standalone Review Report: Nothing came to attention causing belief that the Statement contains material misstatement

2. Consolidated Review Report: Includes results of Proton Remedies Private Limited (subsidiary with total revenues of ₹74.83 lakhs, net profit of ₹0.34 lakhs for H1 FY27)